Lycia Therapeutics, Inc. (LYCA)
| Market Cap | 1.67B |
| Revenue (ttm) | 4.44M -54.9% |
| Net Income | -30.03M |
| EPS | -2.09 |
| Shares Out | 57.68M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 64,884 |
| Open | 29.16 |
| Previous Close | 28.92 |
| Day's Range | 27.94 - 29.16 |
| 52-Week Range | 22.19 - 36.49 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 18, 2026 |
About LYCA
Lycia Therapeutics, Inc., a biotechnology company, engages in the discovery and development of therapeutics designed to degrade disease-causing extracellular proteins for the treatment of autoimmune, inflammatory, and allergic diseases. The company develops the LYTAC platform, a modular technology designed to create therapeutics that selectively reduce the levels of pathogenic proteins. Its therapeutic candidate LCA-0061 degrades immunoglobulin E (IgE) for the treatment of allergic diseases, including food allergy. The company also develops LCA... [Read more]
Financial Performance
Financial StatementsNews
Lycia Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc. (“Lycia”) (Nasdaq: LYCA), a clinical-stage biotechnology company focused on the discovery and development of nov...
Forget Anthropic: Biotech Is Quietly Dominating the IPO Sphere
As investors wait for the Claude developer to file its official IPO paperwork, several biotechs are going public and doing just fine.
Lycia Therapeutics Announces Pricing of Upsized Initial Public Offering
SOUTH SAN FRANCISCO, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc. (“Lycia”) (Nasdaq: LYCA), a clinical-stage biotechnology company focused on the discovery and development of nov...
Lycia Therapeutics Registration statement: Registration filing
Lycia Therapeutics filed a registration statement on October 20, 2026, providing details about a securities offering with the SEC.
Drug developer Lycia Therapeutics targets $938 million valuation in US IPO
Drug developer Lycia Therapeutics said on Tuesday it was targeting a valuation of up to $937.7 million in its US initial public offering, as biotech companies flock to the IPO market.
Lycia Therapeutics files for a $100 million IPO, targeting food allergies and autoimmune diseases
Lycia Therapeutics, a Phase 1 biotech developing protein degraders for food allergy and Graves disease, filed on Monday with the SEC to raise up to $100 million in an initial public offering.
Lycia Therapeutics IPO Registration Document (S-1)
Lycia Therapeutics has filed to go public with an IPO on the NASDAQ
Lycia Therapeutics Registration statement: Registration filing
Lycia Therapeutics filed a registration statement on October 5, 2026, providing details about a securities offering with the SEC.